环索奈德联合孟鲁司特钠治疗儿童哮喘的临床效果  

Clinical Effect of Ciclesonide Combined with Montelukast Sodium in the Treatment of Children with Asthma

作　　者：王忠润 张秀虾 WANG Zhongrun;ZHANG Xiuxia(Maternal and Child Health Hospital of Xiangcheng District in Zhangzhou,Zhangzhou 363000,China)

机构地区：[1]漳州市芗城区妇幼保健院,福建漳州363000 [2]漳州市人民医院

出　　处：《中外医学研究》2021年第11期148-150,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:研究环索奈德联合孟鲁斯特钠治疗儿童哮喘的临床效果。方法:选取2017年9月-2019年9月本院收治的儿童哮喘患者92例,以简单随机化法将其分为对照组和试验组,各46例。对照组采用环索奈德治疗,试验组采用环索奈德联合孟鲁司特钠治疗。比较两组临床疗效、治疗前后肺功能指标、炎症因子,统计不良反应发生情况。结果:试验组治疗总有效率(95.65%)高于对照组(67.39%),差异有统计学意义(P<0.05)。治疗后,试验组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及最大呼气流量(PEF)[(1.77±0.11)L、(2.21±0.17)L、(318.41±25.64)ml/s]高于对照组[(1.53±0.15)L、(1.91±0.14)L、(271.54±25.31)ml/s],差异有统计学意义(P<0.05)。治疗后,试验组血清白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)、超敏C反应蛋白(hs-CRP)水平[(125.18±20.54)ng/L、(548.84±95.38)ng/L、(8.15±1.68)mg/L]低于对照组[(149.31±25.18)ng/L、(789.59±98.56)ng/L、(11.25±1.87)mg/L],差异均有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:与单独给予环索奈德相比,环索奈德联合孟鲁斯特钠治疗儿童哮喘更有利于提高临床效果,改善肺功能,降低炎症因子水平,且安全性佳。Objective:To study the effect of Ciclesonide combined with Montelukast Sodium in the treatment of children with asthma.Method:A total of 92 children with asthma who were admitted to our hospital from September 2017 to September 2019 were selected and divided into the control group and the experimental group by simple randomization method,with 46 cases in each group.The control group was treated with Ciclesonide,and the experimental group was treated with Ciclesonide combined with Montelukast Sodium.The clinical efficacy,lung function indexes and inflammatory factors before and after treatment were compared between the two groups,and the occurrence of adverse reactions was counted.Result:The total effective rate of the experimental group was 95.65%,which was higher than 67.39%of the control group(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC)and peak expiratory flow rate(PEF)of the experimental group[(1.77±0.11)L,(2.21±0.17)L,(318.41±25.64)ml/s]were higher than[(1.53±0.15)L,(2.91±0.14)L,(271.54±25.31)ml/s]of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of serum interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and high-sensitivity C-reactive protein(hs-CRP)in the experimental group[(125.18±20.54)ng/L,(548.84±95.38)ng/L,(8.15±1.68)mg/L]were lower than[(149.31±25.18)ng/L,(789.59±98.56)ng/L,(11.25±1.87)mg/L]of the control group,the differences were statistically significant(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with administering Ciclesonide alone,the combination of Ciclesonide and Montelukast Sodium in the treatment of children with asthma is more beneficial to improve the clinical efficacy,improve lung function,reduce the level of inflammatory factors,and has good safety.

关 键 词：环索奈德 孟鲁斯特钠 儿童哮喘 临床疗效 

分 类 号：R725.6[医药卫生—儿科]